Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases

Journal of Neurochemistry

Volumn 109, Issue 5, 2009, Pages 1427-1439

  Yang, Lichuan ^a   Calingasan, Noel Y ^a   Wille, Elizabeth J ^a   Cormier, Kerry ^b,c   Smith, Karen ^b,c   Ferrante, Robert J ^b,c   Flint Beal, M ^a  

^a Department of Obstetrics Gynecology   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 nitropropionic acid; Huntington's disease; MPTP; Oxidative damage; Parkinson's disease; R6 2 HD mice

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CREATININE; DOPAMINE; GLUTATHIONE; MALONALDEHYDE; TYROSINE 3 MONOOXYGENASE; UBIDECARENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN NERVE CELL; BRAIN PROTECTION; BRAIN SIZE; BRAIN TOXICITY; CONTROLLED STUDY; CORPUS STRIATUM; DNA DAMAGE; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DRUG POTENTIATION; EXPERIMENTAL MODEL; HOMEOSTASIS; HUNTINGTON CHOREA; LIPID PEROXIDATION; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; SURVIVAL; TRANSGENIC MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATINE; DEOXYGUANOSINE; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG THERAPY, COMBINATION; GLUTATHIONE; GLUTATHIONE DISULFIDE; HUNTINGTON DISEASE; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; NITRO COMPOUNDS; PARKINSON DISEASE; PROPIONIC ACIDS; RATS; RATS, INBRED LEW; TYROSINE 3-MONOOXYGENASE; UBIQUINONE;

MUS; MUS MUSCULUS; RATTUS;

EID: 65549091910     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06074.x     Document Type: Article

References (65)

1. Agarwal R. Chase S. D. (2002) Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 775, 121 126. (Pubitemid 34717929)
2. Andreassen O. A., Dedeoglu A., Ferrante R. J. et al. (2001) Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8, 479 491. (Pubitemid 32566138)
3. Beal M. F. Ferrante R. J. (2004) Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5, 373 384. (Pubitemid 38568498)
4. Beal M. F. Shults C. W. (2003) Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease. Biofactors 18, 153 161. (Pubitemid 38030710)
5. Beal M. F., Brouillet E., Jenkins B. G., Ferrante R. J., Kowall N. W., Miller J. M., Storey E., Srivastava R., Rosen B. R. Hyman B. T. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181 4192. (Pubitemid 23299942)
6. Beal M. F., Henshaw D. R., Jenkins B. G., Rosen B. R. Schulz J. B. (1994) Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol. 36, 882 888. (Pubitemid 24979419)
7. Bloom M. Z. (2007) NIH announces phase III clinical trial of creatine for Parkinson's disease. Consult. Pharm. 22, 378.
8. Brewer G. J. Wallimann T. W. (2000) Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J. Neurochem. 74, 1968 1978. (Pubitemid 30217652)
9. Brustovetsky N., Brustovetsky T. Dubinsky J. M. (2001) On the mechanisms of neuroprotection by creatine and phosphocreatine. J. Neurochem. 76, 425 434. (Pubitemid 32097020)
10. Burklen T. S., Schlattner U., Homayouni R., Gough K., Rak M., Szeghalmi A. Wallimann T. (2006) The Creatine Kinase/Creatine Connection to Alzheimer's Disease: CK-Inactivation, APP-CK Complexes and Focal Creatine Deposits. J. Biomed. Biotechnol. 2006, 35936 : 1 11. (Pubitemid 43672669)
11. Cleren C., Yang L., Lorenzo B., Calingasan N. Y., Schomer A., Sireci A., Wille E. J. Beal M. F. (2008) Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J. Neurochem. 104, 1613 1621.
12. Dolder M., Walzel B., Speer O., Schlattner U. Wallimann T. (2003) Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation. J. Biol. Chem. 278, 17760 17766. (Pubitemid 36799379)
13. Echtay K. S., Roussel D., St-Pierre J. et al. (2002) Superoxide activates mitochondrial uncoupling proteins. Nature 415, 96 99. (Pubitemid 34062457)
14. Ernster L. Dallner G. (1995) Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta 1271, 195 204.
15. Ferrante R. J., Andreassen O. A., Jenkins B. G., Dedeoglu A., Kuemmerle S., Kubilus J. K., Kaddurah-Daouk R., Hersch S. M. Beal M. F. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389 4397. (Pubitemid 30396603)
16. Ferrante R. J., Andreassen O. A., Dedeoglu A., Ferrante K. L., Jenkins B. G., Hersch S. M. Beal M. F. (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22, 1592 1599. (Pubitemid 35386278)
17. Ferrante K. L., Shefner J., Zhang H. et al. (2005) Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65, 1834 1836. (Pubitemid 43754429)
18. Fornai F., Schluter O. M., Lenzi P. et al. (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl Acad. Sci. USA 102, 3413 3418. (Pubitemid 40328059)
19. Forsmark-Andree P., Lee C. P., Dallner G. Ernster L. (1997) Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radic. Biol. Med. 22, 391 400. (Pubitemid 27020112)
20. Hart P. E., Lodi R., Rajagopalan B. et al. (2005) Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 62, 621 626. (Pubitemid 40489896)
21. Hausmann O. N., Fouad K., Wallimann T. Schwab M. E. (2002) Protective effects of oral creatine supplementation on spinal cord injury in rats. Spinal Cord 40, 449 456.
22. Hersch S. M. Ferrante R. J. (2004) Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx 1, 298 306. (Pubitemid 46589358)
23. Hersch S. M., Gevorkian S., Marder K. et al. (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66, 250 252. (Pubitemid 43970166)
24. Hofer T., Seo A. Y., Prudencio M. Leeuwenburgh C. (2006) A method to determine RNA and DNA oxidation simultaneously by HPLC-ECD: greater RNA than DNA oxidation in rat liver after doxorubicin administration. Biol. Chem. 387, 103 111. (Pubitemid 43089600)
25. Huntington-Study-Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57, 397 404. (Pubitemid 32757583)
26. Ikeda K., Iwasaki Y. Kinoshita M. (2000) Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. Amyotroph. Lateral Scler. Other Motor. Neuron. Disord. 1, 207 212.
27. Kagan V., Serbinova E. Packer L. (1990) Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. Biochem. Biophys. Res. Commun. 169, 851 857. (Pubitemid 20220697)
28. Kipiani K., Dumont M., Yu F., Wille E., Calingasan N. Y., Beal M. F., Gouras G. K. Lin M. T. (2009) Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. In press.
29. Klivenyi P., Ferrante R. J., Matthews R. T., Bogdanov M. B., Klein A. M., Andreassen O. A., Mueller G., Wermer M., Kaddurah-Daouk R. Beal M. F. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5, 347 350. (Pubitemid 29124375)
30. Klivenyi P., Andreassen O. A., Ferrante R. J., Dedeoglu A., Mueller G., Lancelot E., Bogdanov M., Andersen J. K., Jiang D. Beal M. F. (2000) Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine. J. Neurosci. 20, 1 7. (Pubitemid 30220485)
31. Klivenyi P., Gardian G., Calingasan N. Y., Yang L. Beal M. F. (2003) Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Mol. Neurosci. 21, 191 198. (Pubitemid 39117969)
32. Klivenyi P., Kiaei M., Gardian G., Calingasan N. Y. Beal M. F. (2004a) Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 88, 576 582. (Pubitemid 38140202)
33. Klivenyi P., Calingasan N. Y., Starkov A., Stavrovskaya I. G., Kristal B. S., Yang L., Wieringa B. Beal M. F. (2004b) Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol. Dis. 15, 610 617. (Pubitemid 38429976)
34. Lin M. T. Beal M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787 795. (Pubitemid 44622683)
35. Malcon C., Kaddurah-Daouk R. Beal M. F. (2000) Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res. 860, 195 198. (Pubitemid 30155857)
36. Matthews R. T., Yang L., Browne S., Baik M. Beal M. F. (1998a) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl Acad. Sci. USA 95, 8892 8897. (Pubitemid 28350585)
37. Matthews R. T., Yang L., Jenkins B. G., Ferrante R. J., Rosen B. R., Kaddurah-Daouk R. Beal M. F. (1998b) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 18, 156 163. (Pubitemid 28046777)
38. Matthews R. T., Ferrante R. J., Klivenyi P., Yang L., Klein A. M., Mueller G., Kaddurah-Daouk R. Beal M. F. (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157, 142 149. (Pubitemid 29226877)
39. McCarthy S., Somayajulu M., Sikorska M., Borowy-Borowski H. Pandey S. (2004) Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. Toxicol. Appl. Pharmacol. 201, 21 31. (Pubitemid 39446323)
40. Melnyk S., Pogribna M., Pogribny I., Hine R. J. James S. J. (1999) A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection. J. Nutr. Biochem. 10, 490 497. (Pubitemid 29378307)
41. Meyer L. E., Machado L. B., Santiago A. P., da-Silva W. S., De Felice F. G., Holub O., Oliveira M. F. Galina A. (2006) Mitochondrial creatine kinase activity prevents reactive oxygen species generation: antioxidant role of mitochondrial kinase-dependent ADP re-cycling activity. J. Biol. Chem. 281, 37361 37371. (Pubitemid 46042040)
42. Moon Y., Lee K. H., Park J. H., Geum D. Kim K. (2005) Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J. Neurochem. 93, 1199 1208. (Pubitemid 40776574)
43. NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664 671. (Pubitemid 43739819)
44. Noack H., Kube U. Augustin W. (1994) Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Radic. Res. 20, 375 386. (Pubitemid 24170147)
45. Othman A. A., Shoheib Z. S., Abdel-Aleem G. A. Shareef M. M. (2008) Experimental schistosomal hepatitis: protective effect of coenzyme-Q10 against the state of oxidative stress. Exp. Parasitol. 120, 147 155.
46. Ouary S., Bizat N., Altairac S., Menetrat H., Mittoux V., Conde F., Hantraye P. Brouillet E. (2000) Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 97, 521 530. (Pubitemid 30320758)
47. Papucci L., Schiavone N., Witort E. et al. (2003) Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem. 278, 28220 28228. (Pubitemid 36900022)
48. Pena-Altamira E., Crochemore C., Virgili M. Contestabile A. (2005) Neurochemical correlates of differential neuroprotection by long-term dietary creatine supplementation. Brain Res. 1058, 183 188. (Pubitemid 41416813)
49. Prass K., Royl G., Lindauer U., Freyer D., Megow D., Dirnagl U., Stockler-Ipsiroglu G., Wallimann T. Priller J. (2007) Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J. Cereb. Blood Flow Metab. 27, 452 459. (Pubitemid 46310421)
50. Rakpongsiri K. Sawangkoon S. (2008) Protective effect of creatine supplementation and estrogen replacement on cardiac reserve function and antioxidant reservation against oxidative stress in exercise-trained ovariectomized hamsters. Int. Heart J. 49, 343 354.
51. Shults C. W., Oakes D., Kieburtz K. et al. (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541 1550.
52. Smith K. M., Matson S., Matson W. R., Cormier K., Del Signore S. J., Hagerty S. W., Stack E. C., Ryu H. Ferrante R. J. (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762, 616 626. (Pubitemid 43903119)
53. Somayajulu M., McCarthy S., Hung M., Sikorska M., Borowy-Borowski H. Pandey S. (2005) Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. Neurobiol. Dis. 18, 618 627. (Pubitemid 40332719)
54. Stamelou M., Reuss A., Pilatus U. et al. (2008) Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov. Disord. 23, 942 949.
55. Storch A., Jost W. H., Vieregge P. et al. (2007) Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch. Neurol. 64, 938 944. (Pubitemid 47047992)
56. Sullivan P. G., Geiger J. D., Mattson M. P. Scheff S. W. (2000) Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol. 48, 723 729.
57. Tarnopolsky M. A. Beal M. F. (2001) Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. 49, 561 574. (Pubitemid 32429783)
58. Tomasetti M., Littarru G. P., Stocker R. Alleva R. (1999) Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes. Free Radic. Biol. Med. 27, 1027 1032. (Pubitemid 29507476)
59. Turunen M., Olsson J. Dallner G. (2004) Metabolism and function of coenzyme Q. Biochim. Biophys. Acta 1660, 171 199. (Pubitemid 38125244)
60. Verbessem P., Lemiere J., Eijnde B. O., Swinnen S., Vanhees L., Van Leemputte M., Hespel P. Dom R. (2003) Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 61, 925 930. (Pubitemid 37248646)
61. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M. Przedborski S. (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74, 721 729. (Pubitemid 30053745)
62. Yang L., Calingasan N. Y., Chen J., Ley J. J., Becker D. A. Beal M. F. (2005) A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Exp. Neurol. 191, 86 93. (Pubitemid 39614233)
63. Yang X., Yang Y., Li G., Wang J. Yang E. S. (2008) Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J. Mol. Neurosci. 34, 165 171.
64. Zhang W., Narayanan M. Friedlander R. M. (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. 53, 267 270. (Pubitemid 36164012)
65. Zhu S., Li M., Figueroa B. E. et al. (2004) Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J. Neurosci. 24, 5909 5912. (Pubitemid 38859388)